Reliance Global Group Signs Term Sheet to Acquire Majority Stake in Israeli AI Diagnostic Company, Scentech, Positioning for Entry into the Multi-Billion Dollar Early Disease Detection Market

Core Viewpoint - Reliance Global Group, Inc. has announced a non-binding term sheet to acquire a majority equity position in Scent Medical Technologies Ltd, marking the first strategic acquisition for its new division, Ezra International Group, which focuses on technology-driven investments [1][7]. Company Overview - Reliance Global Group, Inc. operates in the InsurTech sector, utilizing artificial intelligence and cloud-based technologies to enhance efficiencies in the insurance industry. The company offers a suite of business development tools for independent insurance agencies and provides competitive online insurance quotes to consumers [10]. Acquisition Details - The acquisition aims to secure majority ownership of Scentech, contingent upon achieving defined clinical, regulatory, and operational milestones over time. The structure of the transaction is designed to manage development and execution risks through a milestone-based approach [1][7]. Scentech's Technology - Scentech is developing AI technologies for diagnostics, specifically focusing on breath-based molecular testing platforms. Its product candidates, VOX and VocTracer, are intended for early detection of pancreatic cancer and healthcare-associated infections, respectively [2][3][9]. - The initial target markets for Scentech's platform are estimated to represent a potential global market of $5-10 billion, with a commercial plan based on an 'instrument-plus-consumables' model to generate recurring revenue [5]. Development and Validation - Scentech's product candidates are still under development and have not yet received clinical validation or regulatory approval. The company has invested significantly in laboratory infrastructure and automated sampling technologies [4][8]. - The technology aims to provide non-invasive early detection and screening, potentially complementing existing diagnostic pathways [3][4]. Management Perspective - The CEO of Reliance Global Group emphasized the importance of early detection in improving patient outcomes and healthcare economics. The acquisition aligns with the company's mission to leverage AI to disrupt traditional industries and create long-term shareholder value [6][7].